C4 Therapeutics, Inc. (CCCC): A Bull Case Theory

We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC. C4 Therapeutics, Inc.'s share was trading at $1.9600 as of January 29th.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins, stands at the forefront of targeted protein degradation (TPD), a next-generation approach in precision oncology that eliminates disease-causing proteins rather than inhibiting them. Unlike traditional small molecules, degraders achieve deeper, more durable therapeutic effects by fully removing their targets.

C4’s proprietary E3 ligase platform chemistry, protected by robust intellectual property and validated by partnerships with Pfizer and Biogen, has transformed theoretical TPD science into a repeatable, data-driven drug engine. Its TORPEDO platform enables rational degrader design and rapid optimization through in silico modeling, shortening development cycles and deepening its competitive moat.

Strategically, C4 focuses on orphan oncology indications such as synovial sarcoma and multiple myeloma, where its BRD9 and IKZF1/3 degraders, CFT8634 and CFT7455, hold orphan drug designations. This focus allows for smaller, faster pivotal trials, regulatory support, and exclusivity-driven economics, creating a durable market advantage. Capital discipline complements scientific depth: by maintaining a lean cost structure and pursuing milestone-based partnerships, C4 extends its cash runway without diluting ownership.

While the biology of ligase engineering remains complex and scalability challenges persist, C4’s in-house chemistry, clinical networks, and manufacturing know-how have built entry barriers for competitors. Upcoming catalysts include durable efficacy data in orphan cohorts, positive combination results with standard-of-care regimens, and milestone payments from partners that reinforce external validation.

Though class-wide safety and competition risks exist, C4’s combination of technological, market, and operational moats positions it as one of the few independent TPD pure-plays capable of sustained value creation and strategic optionality.

Previously we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted the company’s leadership in gene editing and commercial success with Casgevy alongside Vertex Pharmaceuticals. The company’s stock price has appreciated approximately by 30.21% since our coverage. This is because the thesis played out as Casgevy adoption strengthened. Ridire Research shares a similar but emphasizes on targeted protein degradation as the next frontier in precision oncology.

C4 Therapeutics, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 18 hedge fund portfolios held CCCC at the end of the second quarter which was 19 in the previous quarter. While we acknowledge the potential of CCCC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.